New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
Open Access
- 10 February 2020
- Vol. 7 (2), 12
- https://doi.org/10.3390/children7020012
Abstract
The relapse rate for children with acute myeloid leukemia (AML) remains high despite advancements in risk classification, multi-agent chemotherapy intensification, stem cell transplantation, and supportive care guidelines. Prognosis for this subgroup of children with relapsed/refractory AML remains poor. It is well known that the ceiling of chemotherapy intensification has been reached, limited by acute and chronic toxicity, necessitating alternative treatment approaches. In the last several years, our improved understanding of disease biology and critical molecular pathways in AML has yielded a variety of new drugs to target these specific pathways. This review provides a summary of antibody drug conjugates (ADCs), small molecule inhibitors, and tyrosine kinase inhibitors with an emphasis on those that are currently under clinical evaluation or soon to open in early phase trials for children with relapsed/refractory AML.This publication has 87 references indexed in Scilit:
- Potent inhibition of DOT1L as treatment of MLL-fusion leukemiaBlood, 2013
- MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1LCancer Cell, 2011
- Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapyLeukemia, 2011
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trialLeukemia & Lymphoma, 2009
- Mesothelin, a possible target for immunotherapy, is expressed in primary AML cellsEuropean Journal of Haematology, 2007
- MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapyBlood, 2005
- Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2005
- In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 2004
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993